 |
市場調查報告書
商品編碼
1532624
體外轉錄模板市場 - 按產品類型、疾病、治療、研究階段、最終用途 - 全球預測In-vitro Transcription Templates Market - By Product Type, Disease, Treatment, Research Stage, End-use - Global Forecast |
||||||
在分子生物學的進步以及對基於 RNA 的治療和診斷的需求不斷成長的推動下，體外轉錄模板市場規模預計在 2024 年至 2032 年間將以 19.6% 的複合年成長率成長。體外轉錄模板在產生用於研究和工業應用的 RNA 分子方面發揮著至關重要的作用，包括 RNA 疫苗開發、基因表現研究和 RNA 定序。 RNA技術研究的興起，特別是用於傳染病和癌症免疫療法的mRNA疫苗，也增加了對高品質體外轉錄模板的需求。
更有效率、更具成本效益的轉錄系統的開發以及改進的模板設計技術提高了 RNA 生產的可擴展性和可重複性。基於 RNA 的診斷技術的日益普及，特別是在傳染病爆發期間和遺傳性疾病期間，將進一步刺激產品需求。
該行業分為產品類型、疾病、治療、研究階段、最終用途和地區。
根據產品類型，RNA 模板細分市場預計將在2024 年至2032 年間在體外轉錄模板市場中成長。疫苗、RNA 干擾療法和RNA診斷。一些科學和醫學界也持續探索和擴大 RNA 技術的應用，進一步推動該領域的成長。
按疾病分類，生活方式疾病細分市場的體外轉錄模板行業預計將在2024 年至2032 年實現顯著的複合年成長率。 ，例如糖尿病、心血管疾病、和肥胖。這些疾病通常涉及複雜的分子機制，進一步需要基因表現分析和 RNA 分析。
亞太地區體外轉錄模板市場預計從 2024 年到 2032 年將出現顯著成長。此外，中國、印度和日本等國家日益關注個人化醫療以及慢性病盛行率的上升，推動了對高效 RNA 生產方法的需求。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 基因組學和轉錄組學的進展
- 對 mRNA 疫苗和治療藥物的需求不斷增加
- 分子生物學研究與發展
- 產業陷阱與挑戰
- 可及性和承受能力有限
- 嚴格的監管挑戰
- 成長動力
- 成長潛力分析
- 技術景觀
- 監管環境
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 競爭定位矩陣
- 戰略展望矩陣
第 5 章：市場估計與預測：按產品類型，2021 - 2032 年
- 主要趨勢
- DNA模板
- RNA模板
- 模板和轉錄套件
- 其他產品類型
第 6 章：市場估計與預測：按疾病分類，2021 - 2032 年
- 主要趨勢
- 癌症
- 肺癌
- 乳癌
- 大腸直腸癌
- 攝護腺癌
- 白血病
- 卵巢癌
- 其他癌症
- 傳染病
- 流感
- 伊波拉病毒
- 丙型肝炎病毒
- 人類免疫缺乏病毒（HIV）
- 登革熱病毒
- 其他傳染病
- 生活方式疾病
- 遺傳疾病
- 其他疾病
第 7 章：市場估計與預測：按處理方式，2021 - 2032
- 主要趨勢
- 疫苗
- 治療性
第 8 章：市場估計與預測：按研究階段分類，2021 年 - 2032 年
- 主要趨勢
- 探索性
- 臨床
第 9 章：市場估計與預測：按最終用途，2021 - 2032 年
- 主要趨勢
- 生物技術和製藥公司
- 學術及研究機構
- 合約研究組織
第 10 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 11 章：公司簡介
- Agilent Technologies Inc.
- Bio-Synthesis Inc.
- Bio-Rad Laboratories Inc.
- CINVEN LIMITED
- Danaher Corporation
- Enzynomics Co Ltd.
- Enzo Biochem Inc.
- F. Hoffmann-La Roche Ltd.
- Illumina Inc.
- LGC Limited
- Merck KGaA
- Promega Corporation
- Qiagen N.V.
- Takara Bio Inc.
- Thermo Fisher Scientific Inc.
In-vitro transcription templates market size is anticipated to grow at 19.6% CAGR between 2024 and 2032, driven by advancements in molecular biology and the increasing demand for RNA-based therapeutics and diagnostics. In-vitro transcription templates play a crucial role in generating RNA molecules for research and industrial applications, including RNA vaccine development, gene expression studies, and RNA sequencing. The rise in RNA technology research, especially mRNA vaccines for infectious diseases and cancer immunotherapies, has also heightened the demand for high-quality in-vitro transcription templates.
The development of more efficient and cost-effective transcription systems, along with improved template design techniques has boosted the scalability and reproducibility of RNA production. The rising adoption of RNA-based diagnostics, especially during infectious disease outbreaks and for genetic disorders will further fuel the product demand.
The industry is segmented into product type, disease, treatment, research stage, end-use, and region.
Based on product type, the RNA templates segment is poised to grow in the in-vitro transcription templates market between 2024 and 2032. This dominance is due to its pivotal role in producing high-quality RNA for various applications, including mRNA vaccines, RNA interference therapies, and RNA diagnostics. Several scientific and medical communities are also continuing to explore and expand the applications of RNA technology, further driving the segment growth.
By disease, the in-vitro transcription templates industry from the lifestyle diseases segment is set to witness significant CAGR from 2024 to 2032. This is driven by the growing emphasis on understanding and treating diseases associated with lifestyle factors, such as diabetes, cardiovascular diseases, and obesity. These diseases often involve intricate molecular mechanisms, further necessitating gene expression analysis and RNA profiling.
Asia Pacific in-vitro transcription templates market is expected to witness notable growth from 2024 to 2032. This growth can be attributed to rapid biotechnological advancements, increased research investments, and the rising demand for RNA-based therapies and diagnostics. Moreover, countries like China, India, and Japan, with their increasing focus on personalized medicine and the rising prevalence of chronic diseases, are propelling the need for efficient RNA production methods.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Advancements in genomics and transcriptomics
- 3.2.1.2 Increasing demand for mRNA vaccines and therapeutics
- 3.2.1.3 Research and development in molecular biology
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Limited accessibility and affordability
- 3.2.2.2 Stringent regulatory challenges
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Technological landscape
- 3.5 Regulatory landscape
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive positioning matrix
- 4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 DNA templates
- 5.3 RNA templates
- 5.4 Templates and transcription kits
- 5.5 Other product types
Chapter 6 Market Estimates and Forecast, By Disease, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Cancer
- 6.2.1 Lung cancer
- 6.2.2 Breast cancer
- 6.2.3 Colorectal cancer
- 6.2.4 Prostate cancer
- 6.2.5 Leukemia
- 6.2.6 Ovarian cancer
- 6.2.7 Other cancers
- 6.3 Infectious disease
- 6.3.1 Influenza
- 6.3.2 Ebola virus
- 6.3.3 Hepatitis C virus
- 6.3.4 Human immunodeficiency virus (HIV)
- 6.3.5 Dengue virus
- 6.3.6 Other infectious diseases
- 6.4 Lifestyle disease
- 6.5 Genetic disease
- 6.6 Other diseases
Chapter 7 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Vaccine
- 7.3 Therapeutic
Chapter 8 Market Estimates and Forecast, By Research Stage, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Exploratory
- 8.3 Clinical
Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 Biotechnology and pharmaceutical companies
- 9.3 Academic and research institutes
- 9.4 Contract research organizations
Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 10.1 Key trends
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
- 10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
- 10.6 Middle East and Africa
- 10.6.1 Saudi Arabia
- 10.6.2 South Africa
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
- 11.1 Agilent Technologies Inc.
- 11.2 Bio-Synthesis Inc.
- 11.3 Bio-Rad Laboratories Inc.
- 11.4 CINVEN LIMITED
- 11.5 Danaher Corporation
- 11.6 Enzynomics Co Ltd.
- 11.7 Enzo Biochem Inc.
- 11.8 F. Hoffmann-La Roche Ltd.
- 11.9 Illumina Inc.
- 11.10 LGC Limited
- 11.11 Merck KGaA
- 11.12 Promega Corporation
- 11.13 Qiagen N.V.
- 11.14 Takara Bio Inc.
- 11.15 Thermo Fisher Scientific Inc.
